Role of microRNAs in fluoropyrimidine-related toxicity: what we know.
Eur Rev Med Pharmacol Sci
; 25(8): 3306-3315, 2021 04.
Article
en En
| MEDLINE
| ID: mdl-33928618
ABSTRACT
Although more than half a century has passed since the discovery of fluoropyrimidines, they are still used in the treatment of many types of cancer, and it is estimated that annually two million patients undergo fluoropyrimidine-based chemotherapy. The toxicity resulting from the use of fluoropyrimidines affects about 30-40% of patients, which in some cases may prove to be lethal. The key player in fluoropyrimidine toxicity is DPD activity, and patients with deficits are more likely to develop significant adverse events. In addition to genotyping DPYD variants associated with DPD deficiency, overexpression of miR-27 has also been shown to be a predictive factor for fluoropyrimidine toxicity. This review aims to relate what we know so far about the involvement of miRNA in fluoropyrimidine toxicity and to open new perspectives in this field.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
MicroARNs
/
Fluorouracilo
/
Neoplasias
/
Antimetabolitos Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Eur Rev Med Pharmacol Sci
Asunto de la revista:
FARMACOLOGIA
/
TOXICOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Rumanía